research Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.
EGFR inhibitors can cause skin issues, but managing them is important for treatment success.
Search
for
Sort by
Research
30-60 / 1000+ resultsresearch JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
research The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.
research Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
research Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Cetuximab often causes skin problems, but they can be managed without stopping treatment.
research Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
research “Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors
A new method quickly detects hair changes from EGFR inhibitors using a microscope.
research Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series
Lasers can help reduce skin side effects from cancer treatment.
research Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
Erlotinib can cause excessive eyelash growth.
research 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
research 308 Epidermal keratinocytes regulate bacterial immune responses and host defense through EGFR
EGFR inhibitors cause skin issues and hair loss by weakening skin defenses, suggesting antibiotics and targeted treatments can help.
research Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research Cutaneous consequences of inhibiting EGF receptor signaling in vivo: Normal hair follicle development, but retarded hair cycle induction and inhibition of adipocyte growth in EgfrWa5 mice
Reduced EGFR signaling delays hair cycle and reduces fat growth, but hair development remains normal.
research Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
EGFR-TKIs can cause unexpected skin, nail, and hair issues.
research Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
research Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
Erlotinib may cause scarring hair loss.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
Iressa often causes skin issues like acne and dryness in lung cancer patients.
research Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation
Understanding EGFR's role in skin is crucial for better treatments and managing side effects.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Trichomegaly of the eyelashes following treatment with cetuximab
Cetuximab can cause excessive eyelash growth.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
Understanding EGFR roles could lead to new hair loss treatments.